BridgeMD
Tests treatment safety and results for Cardiovascular Disease and Lipoprotein(a)
Official title An Open Label Extension (OLE) Study (Following Completion of CTQJ230A12301) to Evaluate Long-term Safety and Tolerability of Pelacarsen (TQJ230)
ClinicalTrials.gov ID: NCT07517263
What this study is testing
What is Pelacarsen (TQJ230)?
Pelacarsen (TQJ230) is an investigational medicine, given as a monthly injection under the skin, being studied as a potential treatment for cardiovascular disease and lipoprotein(a).
Also referred to as TQJ230.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- This open-label extension study will provide post-trial access to pelacarsen (TQJ230) to participants who have successfully completed the double-blind parent study (CTQJ230A12301).
- Phase 3: a large, late-stage study
- This is a blinded study.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 to 100
You may be able to join if
- Participants who have provided informed consent prior to initiation of any study-specific activities/procedures.
- Participants who have completed the parent study EOS visit while still on assigned investigational product.
You likely can't join if
- Participants who for any reason permanently discontinued or have interrupted the investigational product for continuous 6 months at EOS during the...
- Participants who have a history or evidence of any clinically significant disorder, condition, or disease that in the opinion of the investigator or...
- Participants are receiving another investigational drug or device before the open-label treatment period.
- Participants have a known sensitivity to the study drug and are deemed as unsuited for the study by the Investigator at Screening visit. Other...
The study team makes the final eligibility decision.
Where it's taking place
- Andalusia, Alabama, United States
- Huntsville, Alabama, United States
- Mobile, Alabama, United States
- Gilbert, Arizona, United States
- Sun City West, Arizona, United States
- Tucson, Arizona, United States
- Little Rock, Arkansas, United States
- Beverly Hills, California, United States
- Covina, California, United States
- Huntington Beach, California, United States
- Irvine, California, United States
- Long Beach, California, United States
- Los Angeles, California, United States
- Northridge, California, United States
- Palo Alto, California, United States
- San Diego, California, United States
- San Francisco, California, United States
- Santa Ana, California, United States
- Stockton, California, United States
- West Hills, California, United States
+ 498 more site(s).
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years to 100 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Andalusia, Alabama, United States; Huntsville, Alabama, United States; Mobile, Alabama, United States; Gilbert, Arizona, United States; Sun City West, Arizona, United States; Tucson, Arizona, United States and 512 more location(s). Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.